Targeting PMN-MDSCs via CD300ld receptor for cancer immunotherapy

Clin Transl Med. 2024 Jan;14(1):e1534. doi: 10.1002/ctm2.1534.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy
  • Myeloid-Derived Suppressor Cells*
  • Neoplasms* / therapy